Related Experiment Video
Updated: Jun 12, 2026

The Nijmegen Hemostasis Assay: Simultaneous Fluorogenic Measurement of Thrombin and Plasmin Generation in a Single Well
Published on: February 27, 2026
Study of 18 functional hemostatic polymorphisms in mucocutaneous bleeding disorders
Ana I Antón1, Rocio González-Conejero, Vanessa Roldán
1Centro Regional de Hemodonación, University of Murcia, Ronda de Garay s/n, Murcia, Spain.
Common genetic variations, or polymorphisms, in hemostasis-related genes may protect children from mild bleeding disorders. These findings suggest a polygenic basis for mucocutaneous bleeding (MCB).
Area of Science:
- Hematology
- Genetics
- Pediatrics
Background:
- Hereditary disorders of primary hemostasis cause mucocutaneous bleeding (MCB) in children.
- Most MCB cases are mild bleeding disorders with complex genetic origins, unlike rare monogenic forms.
Purpose of the Study:
- To investigate the influence of 18 common hemostatic gene polymorphisms on MCB occurrence and severity.
- To explore the polygenic nature of MCB by analyzing the combined effects of these polymorphisms.
Main Methods:
- A case-control study involving 269 pediatric MCB patients and 286 controls.
- Genotyping for 18 common polymorphisms in hemostasis-related genes.
- Statistical analysis, including multivariate analysis and bleeding score assessment.
Main Results:
- Factor V Leiden polymorphism was linked to milder bleeding severity (p=0.013).
- Polymorphisms F13 Leu34, VKORC1 1173T, and non-O blood group alleles offered protection against MCB (ORs 0.66-0.59).
- Combined polymorphisms demonstrated additive protective effects (OR=0.24), supporting a polygenic model for MCB.
Conclusions:
- Common hemostatic gene polymorphisms can protect against MCB in children.
- These findings support the hypothesis that MCB has a complex, polygenic etiology.
- Further research into genetic factors influencing bleeding disorders is warranted.
More Related Videos
Related Concept Videos
Disorders of Hemostasis
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Extrinsic and Intrinsic Pathways of Hemostasis
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Introduction to Hemostasis
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized, and...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Blood Types
ABO blood group
ABO antigens are glycoproteins encoded by genes present on...

